Cerevel Therapeutics Holdings Inc

Cerevel Therapeutics Holdings, Inc. engages in the discovery and development of new therapies for neuroscience diseases. The firm's portfolio focuses on diseases such as schizophrenia, epilepsy, and Parkinson's disease. Its product candidates include CVL-231, Darigabat, Tavapadon, CVL-871, and CVL-936. The company was founded in 2018 and is headquartered in Cambridge, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q2 2024

Earnings data Q3 2024

Cerevel Therapeutics reports successful 2022, eyes transformative neuroscience advancements

Cerevel Therapeutics had a productive year, focusing on transformative neuroscience.
Strong financial position with cash resources to fund operations into 2025.
Facing challenges with trial delays but addressing them with mitigation plans.
Opportunities lie in upcoming data readouts and exploring new indications.

Cerevel Therapeutics reports strong financials, navigates trial challenges for growth

Cerevel Therapeutics is well-positioned financially with a focus on operational efficiency and trial success, supported by strong cash reserves.
The company faces challenges in pipeline management and trial enrollment dynamics, necessitating strategic adjustments and careful oversight.
Opportunities lie in external growth initiatives, potential product approvals, and expanding therapeutic reach through strategic trial designs.

Cerevel Therapeutics advances key programs amidst challenges, eyes growth opportunities

Cerevel Therapeutics is making progress in key programs, leveraging its strong balance sheet and commitment to patients. Challenges in trial delays and patient selection criteria persist, but the company's focus on quality data and financial strength bode well for future growth.

Cerevel Therapeutics excels in Q3 with robust pipeline and financials

Cerevel Therapeutics demonstrated robust performance in Q3 2023, driven by a strong pipeline and solid financial foundation.
While facing challenges like high rollover rates and data disclosure timelines, the company is well-positioned to capitalize on transformative opportunities.
Strategic focus on quality, innovation, and market expansion underscores Cerevel's commitment to advancing novel therapies for neurological disorders.
With key data readouts expected in 2024 and a clear roadmap for regulatory filings, Cerevel is poised for significant growth and impact in the neurology space.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report third quarter 2023 financial results and business updates on Wednesday, November 1, 2023, before the U.S. financial markets open.

Cerevel Therapeutics to Report Third Quarter 2023 Financial Results and Business Updates on Wednesday, November 1, 2023

CAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today the pricing of its previously announced underwritten public offering of 19,728,189 shares of its common stock at a public offering price of $22.81 per share, or approximately $450 million of shares of its common stock. In addition, Cerevel granted the underwriters a 30-day option to purchase up to an additional 2,959,228 shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on October 16, 2023, subject to customary closing conditions.

Cerevel Therapeutics Announces Pricing of $450 Million Public Offering of Common Stock

CAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that it has commenced an underwritten public offering of $400.0 million of shares of its common stock. In connection with this offering, Cerevel expects to grant the underwriters a 30-day option to purchase up to an additional $60.0 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering of common stock is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All shares to be sold in the proposed offering of common stock will be offered by Cerevel.

Cerevel Therapeutics Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that members of the management team will participate in the Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday, September 12, 2023. President and chief executive officer Ron Renaud will participate in a fireside chat at 9:30 AM ET.

Cerevel Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference

NEW YORK , Aug. 18, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Cerevel Therapeutics Holdings, Inc. ("Cerevel" or the "Company") (NASDAQ: CERE).  Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cerevel Therapeutics Holdings, Inc. - CERE

Cerevel Therapeutics Holdings, Inc. experienced a drop in shares due to a delay in releasing top-line results from studies on emraclidine for schizophrenia treatment. Emraclidine is also being developed for Alzheimer's Disease Psychosis, with a phase 1 study already initiated. The company has a well-capitalized financial position and multiple upcoming data readouts for other drugs in its pipeline.

Cerevel: Drop On Data Delay For EMPOWER Program Provides Buy Opportunity

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE ) Q2 2023 Results Conference Call August 2, 2023 8:00 AM ET Company Participants Matthew Calistri - Vice President of Investor Relations Ron Renaud - President and Chief Executive Officer Raymond Sanchez - Chief Medical Officer John Renger - Chief Scientific Officer Susan Altschuller - Interim Chief Financial Officer Conference Call Participants Michael DiFiore - Evercore ISI Mohit Bansal - Wells Fargo Graig Suvannavejh - Mizuho Securities Tazeen Ahmad - Bank of America Paul Matteis - Stifel Joseph Thome - TD Cowen Jeff Hung - Morgan Stanley Michael Yee - Jefferies Charles Duncan - Cantor Fitzgerald Douglas Tsao - H.C. Wainwright Operator Good morning and welcome to Cerevel Therapeutics Second Quarter Financial Results Conference Call.

Cerevel Therapeutics Holdings, Inc. (CERE) Q2 2023 Earnings Call Transcript

Cerevel said it is experiencing delays in some of its clinical trials. The company appointed a new CEO in June.

Why Shares of Cerevel Therapeutics Are Dropping Wednesday

Three new executives added to leadership team: Ron Renaud, Susan Altschuller, Paul Burgess Emraclidine EMPOWER data now expected second half 2024 Darigabat ADAPT trial in panic disorder initiated Cash, cash equivalents, and marketable securities of $825.1 million as of June 30, 2023, expected to support a data-rich 2024 and fund operations into 2025 Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass.

Cerevel Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates

CAMBRIDGE, Mass., July 05, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report second quarter 2023 financial results and business updates on Wednesday, August 2, 2023, before the U.S. financial markets open.

Cerevel Therapeutics to Report Second Quarter 2023 Financial Results and Business Updates on Wednesday, August 2, 2023

Mr. Burgess will be responsible for leading Cerevel's business development and quality teams Mr. Burgess to join Cerevel effective June 20, 2023 CAMBRIDGE, Mass.

Cerevel Therapeutics Appoints Paul Burgess as Chief Business Development and Strategic Operations Officer

Cerevel has some interesting data in various CNS indications. However, the company has a very high valuation. It seems a lot of the company's potential is baked into its price.

Cerevel: High Priced Stock Doing Interesting Science

Susan Altschuller, Ph.D. brings financial management, investor relations, and business planning experience from leading pharmaceutical and biotechnology companies to Cerevel

Cerevel Therapeutics Appoints Susan Altschuller, Ph.D. as Chief Financial Officer

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE ) Q1 2023 Earnings Conference Call May 3, 2023 8:00 AM ET Company Participants Matthew Calistri - Vice President, Corporate Strategy and Investor Relations Tony Coles - Chairperson and Chief Executive Officer Raymond Sanchez - Chief Medical Officer John Renger - Chief Scientific Officer Mark Bodenrader - Interim Chief Financial Officer Conference Call Participants Paul Matteis - Stifel Joseph Thome - TD Cowen Michael Yee - Jefferies Jessica Fye - JP Morgan Graig Suvannavejh - Mizuho Securities Omari Baruti - Goldman Sachs Douglas Tsao - H.C. Wainwright Elaine Kim - Cantor Fitzgerald Operator Good morning and welcome to Cerevel Therapeutics First Quarter Financial Results Conference Call.

Cerevel Therapeutics Holdings, Inc. (CERE) Q1 2023 Earnings Call Transcript

Ron Renaud to succeed Tony Coles, M.D. as CEO, effective June 12, 2023; Dr. Coles will continue as chairperson of the board

Cerevel Therapeutics Appoints Ron Renaud as President and Chief Executive Officer and Reports First Quarter 2023 Financial Results

CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that chairperson and chief executive officer Tony Coles, M.D., will present at the upcoming 2023 BofA Securities Health Care Conference.

Cerevel Therapeutics to Present at the BofA Securities 2023 Health Care Conference

CAMBRIDGE, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report first quarter 2023 financial results and business updates on Wednesday, May 3, 2023, before the U.S. financial markets open.

Cerevel Therapeutics to Report First Quarter 2023 Financial Results and Business Updates on Wednesday, May 3, 2023

CAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that chairperson and chief executive officer Tony Coles, M.D., will participate in a fireside chat at the Stifel Virtual 2023 CNS Days on Wednesday, March 29, 2023 at 10:30 am ET.

Cerevel Therapeutics to Present at the Stifel 2023 CNS Days

CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that chairperson and chief executive officer Tony Coles, M.D., will present at the upcoming 43rd Annual Cowen Health Care Conference.

Cerevel Therapeutics to Present at the 43rd Annual Cowen Health Care Conference

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE ) Q4 2022 Earnings Conference Call February 22, 2023 8:00 AM ET Company Participants Matt Calistri - Vice President of Corporate Strategy & Investor Relations Anthony Coles - Chairperson & Chief Executive Officer Raymond Sanchez - Chief Medical Officer John Renger - Chief Scientific Officer Mark Bodenrader - Interim Chief Financial Officer Conference Call Participants Michael Yee - Jefferies Max Skor - Morgan Stanley Paul Matteis - Stifel Jessica Fye - JPMorgan Umer Raffat - Evercore ISI Charles Duncan - Cantor Mohit Bansal - Wells Fargo Douglas Tsao - H.C. Wainwright Graig Suvannavejh - Mizuho Group Operator Good morning ladies and gentlemen and welcome to Cerevel Therapeutics Fourth Quarter and Full Year 2022 Financial Results Conference Call.

Cerevel Therapeutics Holdings, Inc. (CERE) Q4 2022 Earnings Call Transcript

Emraclidine Phase 1 healthy elderly volunteer trial enrollment underway to support development in Alzheimer's disease psychosis

Cerevel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates

CAMBRIDGE, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report fourth quarter and full year 2022 financial results and business updates on Wednesday, February 22, 2023, before the U.S. financial markets open.

Cerevel Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates on Wednesday, February 22, 2023

Initiated Phase 1 healthy volunteer trial to support development of emraclidine in Alzheimer's disease psychosis in Q4 2022; second potential indication as a once-daily treatment

Cerevel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference and Provide Pipeline Update

CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that chairperson and chief executive officer Tony Coles, M.D., will present at the upcoming 41st Annual J.P. Morgan Healthcare Conference. Dr. Coles will be joined by additional members of the executive team for the question-and-answer portion of the presentation.

Cerevel Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Data provide clear evidence that emraclidine does not induce an increase in blood pressure with chronic dosing in people living with schizophrenia

News for Cerevel Therapeutics Holdings Inc Stock (CERE)